Purple Book product · Biosimilar 351(k)
Alymsys
bevacizumab-maly
At a glance
Apr 13, 2022
Approved
Biosimilar 351(k)
License type
Rx
Marketing
No
Patents listed
Key dates
Approval
Approval date of this BLA submission.
Apr 13, 2022
4 yr 2 mo ago
Today
Pharmaceutical detail
Strength
100MG/4ML (25MG/ML)
Dosage form
Injection
Route
Intravenous
Presentation
Single-Dose Vial
Center
CDER
License number
2241
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Reference product family
View full familyBiosimilar of bevacizumab (Avastin)
Patent list (22)
| Patent | Expires | In | Source |
|---|---|---|---|
| 9,795,672 | May 28, 2024 | 2 yr 1 mo ago | FDA |
| 7,485,704 | Mar 08, 2025 | 1 yr 3 mo ago | FDA |
| 10,906,986 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 11,078,294 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 8,574,869 | Jul 08, 2028 | in 2 yr 2 mo | FDA |
| 8,460,895 | Aug 08, 2029 | in 3 yr 3 mo | FDA |
| 10,982,003 | Aug 06, 2030 | in 4 yr 3 mo | FDA |
| 9,714,293 | Aug 06, 2030 | in 4 yr 3 mo | FDA |
| 8,512,983 | Jan 04, 2031 | in 4 yr 8 mo | FDA |
| 10,011,856 | May 26, 2031 | in 5 yr 1 mo | FDA |
| 10,662,237 | Aug 07, 2031 | in 5 yr 3 mo | FDA |
| 10,704,071 | Aug 18, 2031 | in 5 yr 3 mo | FDA |
| 9,487,809 | Jan 14, 2032 | in 5 yr 8 mo | FDA |
| 10,513,697 | Sep 17, 2032 | in 6 yr 5 mo | FDA |
| 10,906,934 | Oct 12, 2033 | in 7 yr 6 mo | FDA |
| 10,017,732 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 10,676,710 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 10,829,732 | Mar 14, 2034 | in 7 yr 11 mo | FDA |
| 9,441,035 | Apr 23, 2034 | in 8 yr | FDA |
| 10,274,466 | Jul 11, 2035 | in 9 yr 3 mo | FDA |
| 10,208,355 | Jul 14, 2035 | in 9 yr 3 mo | FDA |
| 10,336,983 | Jul 31, 2035 | in 9 yr 3 mo | FDA |
Taxonomy and ontology
11 termscenter
Center for Drug Evaluation and Research
center · CDER
application pathway
Biologics License Application
blaNumber · BLA
license type
351(k) Biosimilar
blaType · 351(k) Biosimilar
application pathway
Section 351(k) Biosimilar or Interchangeable
blaType · 351(k)
product role
Biosimilar
blaType · Biosimilar
marketing status
Prescription
marketingStatus · Rx
licensure status
Licensed
licensure · Licensed
route
Intravenous
routeOfAdministration · Intravenous
dosage form
Injection
dosageForm · Injection
source kind
Monthly Download
sourceKind · monthly_download
- Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
- Food and Drug Administrationsource forMonthly Download
- Biologics License Applicationparent ofSection 351(a) Biologic
- Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
- Section 351(k) Biosimilar or Interchangeablemaps to351(k) Biosimilar
- Section 351(k) Biosimilar or Interchangeablemaps to351(k) Interchangeable
Source provenance
